Validating digital health technologies for monitoring biomarkers in ADRD clinical trials (R61/R33 - Clinical Trials Optional)

The summary for the Validating digital health technologies for monitoring biomarkers in ADRD clinical trials (R61/R33 - Clinical Trials Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Validating digital health technologies for monitoring biomarkers in ADRD clinical trials (R61/R33 - Clinical Trials Optional): The goal of this RFA is to enable partnerships between academics and companies that make wearable devices to validate their digital health technologies (DHTs) as digital monitoring biomarkers in ADRD populations. Applications will be required to optimize their DHTs in diverse patient populations from two or more early stage clinically diagnosed ADRD. Studies must demonstrate the accuracy of the digital markers to differentiate clinically meaningful features (such as sleep stage) and establish the longitudinal relationship between the features measured with quality-of-life metrics. Studies should also establish the relationship with one or more analytically validated ADRD biomarker(s) and standard cognitive assessments to validate the relationship between the features measured by the DHTs with the underlying pathophysiology or cognitive concept it reflects. An ideal outcome would be evidence for incorporating these DHT measures as monitoring biomarkers in future ADRD clinical trials. A 5-year phased mechanism is requested with a 2-year start-up phase (R61) to ensure adequate community engagement and recruitment of diverse patient populations, and to conduct pilot studies to optimize the algorithms; this will be followed by a 3-year R33 validation phase.

Federal Grant Title:	Validating digital health technologies for monitoring biomarkers in ADRD clinical trials (R61/R33 - Clinical Trials Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-NS-24-026
Type of Funding:	Grant
CFDA Numbers:	93.853, 93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 17th, 2023
Original Application Deadline:	November 17th, 2023
Posted Date:	August 1st, 2023
Creation Date:	August 1st, 2023
Archive Date:	December 23rd, 2023
Total Program Funding:
Maximum Federal Grant Award:	$1,000,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	August 2nd, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-026.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required); • Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VC...; • NINDS Child Neurology Career Development Program (CNCDP) (K12 - Clinical Trial Not Allowed...; • Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 C...; • The NINDS Human Biospecimen and Data Repository (U24 - Clinical Trial Not Allowed); • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44); • NINDS Institutional Center Core Grants to Support Neuroscience Research; • Career Development Award to Promote Diversity in Neuroscience Research
More Grants from the National Institutes of Health: • Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinic...; • Immune Tolerance Network (UM1 Clinical Trial Required); • Coordinating Center for National Resource Network for the Study of Human Auditory and Vest...; • National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Cl...; • Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Interven...